Cargando…

Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment

BMS‐986263 is a retinoid‐conjugated lipid nanoparticle delivering small interfering RNA designed to inhibit synthesis of HSP47 protein, a collagen‐specific chaperone protein involved in fibrosis development. This is a phase I, open‐label, two‐part study evaluating pharmacokinetics and safety of BMS‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qosa, Hisham, de Oliveira, Claudia H. M. C., Cizza, Giovanni, Lawitz, Eric J., Colletti, Nicholas, Wetherington, Jeffrey, Charles, Edgar D., Tirucherai, Giridhar S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582666/ https://www.ncbi.nlm.nih.gov/pubmed/37654022 http://dx.doi.org/10.1111/cts.13581

Ejemplares similares

BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
por: Lawitz, Eric J., et al.
Publicado: (2021)

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
por: Charles, Edgar D., et al.
Publicado: (2018)

Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants
por: Lee, Sun Ku, et al.
Publicado: (2017)

Anti-HSP47 siRNA lipid nanoparticle ND-L02-s0201 reverses interstitial pulmonary fibrosis in preclinical rat models
por: Liu, Yun, et al.
Publicado: (2021)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
por: Wang, Xiaoli, et al.
Publicado: (2013)

Hsp70 Knockdown by siRNA Decreased Collagen Production in Keloid Fibroblasts
por: Shin, Jung U, et al.
Publicado: (2015)

Pharmacokinetic Behaviors of Intravenously Administered siRNA in Glandular Tissues
por: Huang, Yuanyu, et al.
Publicado: (2016)

A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
por: Qureshi, Irfan A., et al.
Publicado: (2018)

Identification of HSP47 Binding Site on Native Collagen and Its Implications for the Development of HSP47 Inhibitors
por: Cai, Haiyan, et al.
Publicado: (2021)

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

NADPH oxidase p47phox siRNA attenuates adventitial fibroblasts proliferation and migration in apoE(-/-) mouse
por: Xu, Fang, et al.
Publicado: (2015)

Safety, Pharmacokinetics, and Pharmacodynamics of CC‐90001 (BMS‐986360), a c‐Jun N‐terminal Kinase Inhibitor, in Phase 1 Studies in Healthy Participants
por: Ye, Ying, et al.
Publicado: (2022)

Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA
por: Yingyuad, Peerada, et al.
Publicado: (2014)

Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
por: Berezhnoy, Alexey, et al.
Publicado: (2012)

Where should siRNAs go: applicable organs for siRNA drugs
por: Ahn, Insook, et al.
Publicado: (2023)

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017)

Multifunctional selenium nanoparticles as carriers of HSP70 siRNA to induce apoptosis of HepG2 cells
por: Li, Yinghua, et al.
Publicado: (2016)

Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing
por: Cai, Weiguo, et al.
Publicado: (2020)

Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management
por: Abd El-Fattah, Eslam E., et al.
Publicado: (2022)

p47phox siRNA-Loaded PLGA Nanoparticles Suppress ROS/Oxidative Stress-Induced Chondrocyte Damage in Osteoarthritis
por: Shin, Hyo Jung, et al.
Publicado: (2020)

Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses
por: Li, Simin, et al.
Publicado: (2023)

MiR-29/Hsp47 in ECM network
por: Xu, Ren
Publicado: (2015)

HSP47 levels determine the degree of body adiposity
por: Shin, Jihoon, et al.
Publicado: (2023)

HSP47: A Therapeutic Target in Pulmonary Fibrosis
por: Sakamoto, Noriho, et al.
Publicado: (2023)

Construction of the MPI BMS Prototype Chamber
por: Bratzler, U, et al.
Publicado: (1997)

Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles
por: Mui, Barbara L, et al.
Publicado: (2013)

A Tetrahymena Hsp90 co-chaperone promotes siRNA loading by ATP-dependent and ATP-independent mechanisms
por: Woehrer, Sophie L, et al.
Publicado: (2015)

Targeted Delivery of siRNA
por: Oliveira, Sabrina, et al.
Publicado: (2006)

siRNA for Influenza Therapy
por: Barik, Sailen
Publicado: (2010)

Retrovirus-delivered siRNA
por: Devroe, Eric, et al.
Publicado: (2002)

Dendrimers for siRNA Delivery
por: Biswas, Swati, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hqa2drgla519ab98r2k3c5utoa